Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Menin Inhibitor Induces Activity in Patients With Refractory AML

December 5th 2020

December 5, 2020 - KO-539, an oral, selective menin-inhibitor, demonstrated activity in patients with relapsed/refractory acute myeloid leukemia in preliminary findings from the ongoing first-in-human KOMET-001 trial.

Ruxolitinib Demonstrates Superior Efficacy Over Best Available Therapy in Chronic GVHD

December 5th 2020

December 5, 2020 - Ruxolitinib was found to elicit a significantly higher overall response rate, a substantially greater improvement in failure-free survival, and greater symptom improvement versus best available therapy in patients with chronic graft-versus-host disease with an inadequate response to corticosteroids.

Next-Generation CD47 Blocker ALX148/Azacitidine Combo Under Exploration in MDS

December 4th 2020

December 4, 2020 - The first patient with higher-risk myelodysplastic syndrome has been dosed with a novel combination comprised of the next-generation CD47 blocker ALX148 plus azacitidine as part of the phase 1/2 ASPEN-02 study, the first of several planned studies to examine the agent in those with myeloid malignancies.

Novel Approaches Challenge Toxicity Restraints in Classical Hodgkin Lymphoma

December 4th 2020

The ability to increase the efficacy and decrease the toxicity of treatment regimens in classical Hodgkin lymphoma had stood at odds until the introduction of response-adapted treatment approaches, antibody-drug conjugates, and checkpoint inhibitors to the paradigm.

Treatment Considerations in Newly Diagnosed CLL

December 4th 2020

Drs Stilgenbauer and Ghia provide insight on initial treatment considerations for patients with newly diagnosed chronic lymphocytic leukemia.

Dr. Shah on Dosing Tandem Receptor CAR T-Cell Therapy in B-Cell Malignancies

December 3rd 2020

Nirav N. Shah, MD, associate professor, Medical College of Wisconsin, discusses the dosing of tandem receptor CAR T-cell therapy in B-cell malignancies.

MLL Fusion Proteins Emerge as a Promising Target in AML

December 3rd 2020

Novel agents that disrupt protein-protein interactions in the MLL network may be the key to unlocking new therapeutic avenues for patients with acute leukemias.

Dr. Sehgal on Key Targetable Alterations in AML

December 2nd 2020

Alison R. Sehgal, MD, discusses key targetable alterations in acute myeloid leukemia.

Dr. Ayers on the Evolving Treatment Landscape in CLL

December 2nd 2020

Emily C. Ayers, MD, hematologist/oncologist, assistant professor, University of Virginia Health, discusses the evolving treatment landscape in chronic lymphocytic leukemia.

The Therapeutic Toolkit for MDS-Associated Anemia Adds Luspatercept

December 2nd 2020

Joseph G. Jurcic, MD, discusses strategies to optimize patient selection for luspatercept in MDS.

Novel Venetoclax/Decitabine Dosing Schedule Demonstrates Safety, Efficacy in Older Patients With Newly Diagnosed AML

December 1st 2020

The combination of 10-day decitabine with venetoclax elicited responses and was found to be well tolerated in older patients with newly diagnosed acute myeloid leukemia who are ineligible for chemotherapy.

Response-Based Radiation Is Effective, Safe in Pediatric High-Risk Hodgkin Lymphoma

December 1st 2020

The use of response-based consolidation coupled with radiation therapy was found to be effective and well tolerated, with low failure rates, in pediatric patients with high-risk classical Hodgkin lymphoma.

Dr. Nagle on Investigational Cellular Therapies in Multiple Myeloma

November 30th 2020

Sarah Nagle, MD, assistant professor of medicine, School of Medicine, Oregon Health & Science University, discusses investigational cellular therapies in multiple myeloma.

Dr. Ruan on Treatment Considerations for Relapsed/Refractory MCL

November 30th 2020

Jia Ruan, MD, PhD, associate professor of clinical medicine, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses treatment considerations for patients with relapsed/refractory mantle cell lymphoma.

FDA Grants Eprenetapopt Fast Track Status in TP53-Mutant AML

November 30th 2020

November 30, 2020 - The FDA has granted a fast track designation to eprenetapopt as a treatment for patients with TP53-mutant acute myeloid leukemia.

FDA Grants Belumosudil Priority Review for Chronic GVHD

November 30th 2020

The FDA has granted a priority review designation to a new drug application for belumosudil for the treatment of patients with chronic graft-versus-host disease.

Panelists Parse Out Answers to Key Questions in Hematologic Malignancies

November 25th 2020

Stephen A. Strickland, MD, BS, MS, MSCI, relays insightful questions from the audience to the speakers, who provided insight into how they are navigating the evolving treatment landscape of hematologic malignancies.

Dr. Dorritie on Determining Transplant Eligibility in Multiple Myeloma

November 24th 2020

Kathleen A. Dorritie, MD, discusses transplant eligibility in multiple myeloma.

CAR T-Cell Therapy Transforms Leukemia and Lymphoma Treatment, But Toxicity Concerns Remain

November 24th 2020

Olalekan O. Oluwole, MBBS, MD, discusses the approvals of tisagenlecleucel and axicabtagene ciloleucel, along with several research efforts that have been dedicated to the development and exploration of CAR T-cell therapies in the realm of leukemias and lymphomas.

NCCN Grants Category 2A Recommendation to Decitabine/Cedazuridine Combo for MDS

November 23rd 2020

November 23, 2020 - The National Comprehensive Cancer Network has updated its Clinical Practice Guidelines in Oncology for Myelodysplastic Syndromes (MDS) to include the combination of decitabine and cedazuridine as a category 2a recommendation for the treatment of adult patients with intermediate- and high-risk MDS.